Apo-Methyldopa
Brand names,
Apo-Methyldopa
Analogs
Apo-Methyldopa
Brand Names Mixture
Apo-Methyldopa
Chemical_Formula
C56H71N9O23S
Apo-Methyldopa
RX_link
http://www.rxlist.com/cgi/generic4/mycamine.htm
Apo-Methyldopa
fda sheet
Apo-Methyldopa
msds (material safety sheet)
Apo-Methyldopa
Synthesis Reference
No information avaliable
Apo-Methyldopa
Molecular Weight
1270.28 g/mol
Apo-Methyldopa
Melting Point
No information avaliable
Apo-Methyldopa
H2O Solubility
Freely soluble as sodium salt (> 200mg/mL)
Apo-Methyldopa
State
Solid
Apo-Methyldopa
LogP
No information avaliable
Apo-Methyldopa
Dosage Forms
Powder for solution (for injection)
Apo-Methyldopa
Indication
For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Apo-Methyldopa
Pharmacology
Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.
Apo-Methyldopa
Absorption
No information avaliable
Apo-Methyldopa
side effects and Toxicity
Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.
Apo-Methyldopa
Patient Information
No information avaliable
Apo-Methyldopa
Organisms Affected
Aspergillis, Candida and other fungi